The future of non-human primate use in mAb development.
It has been predicted that the use of non-human primates (NHPs) is going to increase considerably in the development of monoclonal antibodies (mAbs). Opportunities exist to focus on a rigorous, science-based approach to drug development, however, which will minimize this increase. In this article, the authors review current and future NHP use in mAb development based on surveys, experience and expert opinion and propose a framework that will minimize future NHP use and continue to support science and innovation.
Chapman
Kathryn L
KL
National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK. kathryn.chapman@nc3rs.org.uk
Pullen
Nick
N
Andrews
Laura
L
Ragan
Ian
I
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D005544:Forecasting; D006801:Humans; D008252:Macaca fascicularis
D000911:Antibodies, Monoclonal